The usefulness of the total metabolic tumor volume for predicting the postoperative recurrence of thoracic esophageal squamous cell carcinoma

Table 2 Log-rank test of PET parameters and clinicopathological factors for relapse-free survival (RFS)

Parameters	n	5-yrsurvival rate	p-value
Age:
< 66	78	59.9%	0.514
≥ 66	85	55.6%	0.514
Gender:
Male	135	58.8%	0.373
Female	28	51.8%	0.373
Location:
Ut-Mt	121	58.0%	0.878
Lt	42	56.6%	0.878
Mt-Lt	138	59.6%	0.134
Ut	25	47.7%	0.134
cT stage:
cT1–2	128	66.0%	< 0.001
cT3	35	27.1%	< 0.001
cN stage:
cN0	113	68.3%	< 0.001
cN1–2	50	32.8%	< 0.001
cM stage:
cM0	162	58.0%	0.165
cM1(LYM)	1	NA	0.165
pT stage:
pT1–2	114	69.8%	< 0.001
pT3–4	49	28.2%	< 0.001
pN stage:
pN0–1	133	67.4%	< 0.001
pN2–3	30	14.0%	< 0.001
pM stage:
pM0	159	58.5%	0.035
pM1(LYM)	4	NA	0.035
peakSUVmax:
< 4.43	71	74.9%	< 0.001
≥ 4.43	92	44.1%	< 0.001
TMTV:
< 3.82	76	77.9%	< 0.001
≥ 3.82	87	39.7%	< 0.001
wTLG:
< 13.46	78	73.1%	< 0.001
≥ 13.46	85	43.2%	< 0.001
hSULpeak:
< 2.64	68	75.2%	< 0.001
≥ 2.64	95	44.8%	< 0.001

hSULpeak Highest lean body mass peak standardized uptake value, Lt Lower thoracic esophagus, Mt Middle thoracic esophagus, LYM Supraclavicular lymph node metastasis, PeakSUVmax Peak maximum standardized uptake value, PET Positron emission tomography, TMTV Total metabolic tumor volume, Ut Upper thoracic esophagus, wTLG Whole-body total lesion glycolysis

ISSN: 1471-2407